Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL

Starting soon · Phase 1/Phase 2

Conditions studied: PTCL, Refractory

In brief

To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).

Key facts

Study ID

NCT07493330

Run by

Ruijin Hospital

People needed

86

Starts

2026-03-23

Expected to finish

2030-12-12

Last updated by the study team

2026-04-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years, male or female.
• Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification
• Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment.
• Tumor tissue genotyping performed and results available prior to enrollment.
• ECOG 0, 1, or 2.
• Life expectancy greater than 3 months.
• Adequate organ function
• Contraception during study
• Informed consented

You may not qualify if…

• Has a prior malignancy other than the malignancies under study within 3 years without relieve
• Primary CNS lymphoma
• Known hypersensitivity to any study drug.
• Pregnant or lactation
• Active infection.
• Diseases and medical history:
• Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers
• Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
• Has a history of psychoactive substance abuse that cannot be discontinued
• Has any severe and/or uncontrolled disease.
• Uncontrollable autoimmune disease,
• Not able to comply to the protocol for mental or other unknown reasons
• Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.